BiotechTube

Tivantinib + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatocellular Carcinoma

Conditions

Hepatocellular Carcinoma

Trial Timeline

Dec 27, 2012 → Jul 31, 2017

NCT ID
NCT01755767

About Tivantinib + Placebo

Tivantinib + Placebo is a phase 3 stage product being developed by Daiichi Sankyo for Hepatocellular Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01755767. Target conditions include Hepatocellular Carcinoma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT01755767Phase 3Completed
NCT01699061Phase 1Completed

Competing Products

20 competing products in Hepatocellular Carcinoma

See all competitors
ProductCompanyStageHype Score
CT-01 + EVEROLIMUSCaptor TherapeuticsPhase 1
25
ateganosine + CadonilimabMAIA BiotechnologyPhase 1
25
Ramucirumab + PlaceboEli LillyPhase 3
77
ERY974 + Tocilicumab + Atezolizumab + BevacizumabChugai PharmaceuticalPhase 1
33
Atezolizumab + Bevacizumab + TiragolumabChugai PharmaceuticalPhase 3
77
GC33(RO5137382) + SorafenibChugai PharmaceuticalPhase 1
33
CS-1008 2 mg/kg + Sorafenib + CS-1008 6/2 mg/kg + CS-1008 6/6 mg/kg + CS-1008 4 mg/kg + CS-1008 6 mg/kgDaiichi SankyoPhase 2
52
OSI-906 + PlaceboAstellas PharmaPhase 2
52
Enzalutamide + PlaceboAstellas PharmaPhase 2
52
Enzalutamide + Enzalutamide with SorafenibAstellas PharmaPhase 1
33
Recombinant oncolytic virus M1, anti PD-1 antibody, ApatinibSun PharmaceuticalPhase 1
33
Irinotecan + Sonidegib + SorafenibSun PharmaceuticalPhase 2
52
mFOLFOX7 combined with Camrelizumab and apatinibSun PharmaceuticalPhase 2
52
camrelizumab& apatinibSun PharmaceuticalPhase 2
52
LenvatinibEisaiPre-clinical
23
Lenvatinib PillEisaiPhase 2
52
Sorafenib + SorafenibEisaiPhase 1/2
41
LenvatinibEisaiPhase 2
52
Lenvatinib + NivolumabEisaiPhase 2
52
H3B-6527EisaiPhase 1
33

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85